Allstate Corp Makes New Investment in Becton, Dickinson and Company $BDX

Allstate Corp bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 10,476 shares of the medical instruments supplier’s stock, valued at approximately $1,961,000.

Other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC raised its position in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. Empowered Funds LLC increased its stake in shares of Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after purchasing an additional 1,354 shares during the last quarter. Diversified Trust Co lifted its position in shares of Becton, Dickinson and Company by 6.2% during the 2nd quarter. Diversified Trust Co now owns 1,262 shares of the medical instruments supplier’s stock worth $217,000 after buying an additional 74 shares during the last quarter. CX Institutional boosted its stake in Becton, Dickinson and Company by 13.4% in the second quarter. CX Institutional now owns 1,671 shares of the medical instruments supplier’s stock valued at $288,000 after buying an additional 198 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its position in Becton, Dickinson and Company by 98.7% in the second quarter. Farther Finance Advisors LLC now owns 4,000 shares of the medical instruments supplier’s stock valued at $689,000 after acquiring an additional 1,987 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have commented on BDX. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Jefferies Financial Group upped their price target on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Royal Bank Of Canada lifted their price target on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 17th. Finally, Stifel Nicolaus increased their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Four analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $207.64.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares in the company, valued at $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,662 shares of company stock worth $535,246 over the last 90 days. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $203.31 on Wednesday. The firm has a market capitalization of $57.92 billion, a P/E ratio of 34.87, a P/E/G ratio of 2.29 and a beta of 0.23. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The stock has a 50 day moving average price of $196.68 and a two-hundred day moving average price of $189.89. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. The business had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date was Monday, December 8th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.